KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.
dc.contributor.author | Doherty, Gary | en |
dc.contributor.author | Kerr, Emma M | en |
dc.contributor.author | Pedro Martins, Carla | en |
dc.date.accessioned | 2018-03-29T13:07:14Z | |
dc.date.available | 2018-03-29T13:07:14Z | |
dc.date.issued | 2017-05 | en |
dc.identifier.issn | 1471-4914 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/274499 | |
dc.format.medium | Print-Electronic | en |
dc.language | eng | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Humans | en |
dc.subject | Leukemia | en |
dc.subject | Benzamides | en |
dc.subject | Diphenylamine | en |
dc.subject | MAP Kinase Kinase 1 | en |
dc.subject | MAP Kinase Kinase 2 | en |
dc.subject | Gene Dosage | en |
dc.subject | Allelic Imbalance | en |
dc.subject | Models, Theoretical | en |
dc.subject | Proto-Oncogene Proteins p21(ras) | en |
dc.title | KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers. | en |
dc.type | Article | |
prism.endingPage | 378 | |
prism.issueIdentifier | 5 | en |
prism.publicationDate | 2017 | en |
prism.publicationName | Trends in molecular medicine | en |
prism.startingPage | 377 | |
prism.volume | 23 | en |
dc.identifier.doi | 10.17863/CAM.21617 | |
dcterms.dateAccepted | 2017-03-20 | en |
rioxxterms.versionofrecord | 10.1016/j.molmed.2017.03.005 | en |
rioxxterms.version | AM | * |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | en |
rioxxterms.licenseref.startdate | 2017-05 | en |
dc.contributor.orcid | Doherty, Gary Joseph [0000-0002-8158-8111] | |
dc.identifier.eissn | 1471-499X | |
rioxxterms.type | Journal Article/Review | en |
pubs.funder-project-id | MRC (MC_UU_12022/1_do not transfer?) | |
pubs.funder-project-id | Medical Research Council (MC_UU_12022/4) | |
rioxxterms.freetoread.startdate | 2018-03-31 |